We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Advanced Liquid Logic Acquires Nanolytics

By Labmedica staff writers
Posted on 12 Mar 2007
Advanced Liquid Logic (Morrisville, NC, USA) a microfluidics "lab-on-a-chip” spinout from Duke University's Pratt School of Engineering (Durham, NC, USA), announced that it has acquired Nanolytics, Inc. More...
The terms of the acquisition were not disclosed.

"This clearly gives us the high ground in the race for both demonstrated progress and intellectual property in this exciting new technology. The technology has huge potential for miniaturizing test equipment and performing complex tests at the point of sample collection,” said Richard West, CEO of Advanced Liquid Logic. "Not only will we benefit from Nanolytics' patents but from the continuing contributions of key Nanolytics employees as well.”

Nanolytics, founded in the late 1990s, received several million dollars in commercial and government support prior to the transaction. Michael Pollack, an early Nanolytics employee, left Nanolytics to further develop the technology at Duke University and then went on to co-found Advanced Liquid Logic in 2004. "Our own excellent team has brought us to this important milestone,” said Advanced Liquid Logic's other co-founder Vamsee Pamula. "While the technology is exciting, it takes much more than that to create a promising company with the resources to become the industry leader.”

Advanced Liquid Logic is leading the development of a new technology for micro-liquid-handling called digital microfluidics. Small droplets can be moved under direct, programmable, software control to perform complex, liquid-based testing in a palmtop-sized device. The company's primary focus is developing products for medical diagnostics and monitoring. The company has demonstrated clinical chemistry assays, immunoassays, and polymerase chain reaction (PCR) on the technology platform and is in the process of implementing DNA sequencing, analyte sorting, test multiplexing, and integrated sample preparation.


Related Links:
Advanced Liquid Logic
Duke University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.